EVFM - Evofem Biosciences, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
7.12
+0.10 (+1.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.02
Open6.85
Bid0.00 x 0
Ask0.00 x 0
Day's Range6.80 - 7.30
52 Week Range1.80 - 15.78
Volume14,640
Avg. Volume12,854
Market Cap126.475M
Beta3.21
PE Ratio (TTM)N/A
EPS (TTM)-1.27
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • Evofem Biosciences Announces Proposed Public Offering of Common Stock
    PR Newswire2 days ago

    Evofem Biosciences Announces Proposed Public Offering of Common Stock

    SAN DIEGO, April 24, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today the launch of an underwritten public offering of $40.0 million of its common stock. All of the shares in the offering are to be sold by Evofem. As part of the offering, Evofem expects to grant the underwriters a 30-day option to purchase up to an additional $6.0 million of its common stock offered in the public offering at the public offering price, less the underwriting discount and commissions.

  • Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia
    PR Newswire2 months ago

    Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia

    SAN DIEGO, Feb. 21, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of urogenital chlamydia in women. Amphora is an investigational drug being studied for the prevention of certain sexually transmitted infections (STIs) and as an on-demand, non-hormonal vaginal contraceptive.

  • Evofem Biosciences to Present at RBC Global Healthcare Conference
    PR Newswire2 months ago

    Evofem Biosciences to Present at RBC Global Healthcare Conference

    SAN DIEGO , Feb. 16, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's ...

  • Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule
    PR Newswire2 months ago

    Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule

    SAN DIEGO, Feb. 15, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, announced early completion of enrollment in its Phase 3 clinical trial evaluating Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of pregnancy. This single-arm, open-label, multicenter, Phase 3 clinical trial enrolled over 1,350 women aged 18-35 at risk of pregnancy at over 100 centers in the United States. The primary endpoint of the study is the contraceptive efficacy of Amphora over seven cycles of use.

  • Evofem Biosciences Inc (NASDAQ:EVFM): Is Healthcare Attractive Relative To NasdaqCM Peers?
    Simply Wall St.3 months ago

    Evofem Biosciences Inc (NASDAQ:EVFM): Is Healthcare Attractive Relative To NasdaqCM Peers?

    Evofem Biosciences Inc (NASDAQ:EVFM), a $159.81M small-cap, operates in the healthcare industry, which continues to endure a more demanding healthcare agenda, and the global need for innovative, cost-effective medicines continuesRead More...

  • Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019
    PR Newswire3 months ago

    Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019

    SAN DIEGO, Jan. 23, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM), a clinical-stage specialty biopharmaceutical company focused on the development and commercialization of women's healthcare products, today announced enrollment of the first patient in a Phase 2b/3 clinical trial evaluating Amphora and its ability to prevent urogenital chlamydia and gonorrhea in women.  Amphora is an investigational compound being studied for the prevention of certain reproductive tract infections and as an on-demand, non-hormonal vaginal contraceptive. "We are excited to initiate this trial and expect that it will provide data in support of Amphora's use to prevent sexually transmitted infections, or STIs, in women when administered within one hour prior to sex," said Kelly Culwell, MD, Chief Medical Officer for Evofem Biosciences.